FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | Merck

Merck invests $300M in vaccine expansion

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Merck's decision to pump $300 million into an expansion of its Durham, NC vaccine facility is seen by analysts as part of a coordinated effort to solidify a leading role in a booming global vaccines market. The work in North Carolina should be completed by 2010, a year before Merck opens a new, $300 million vaccine plant in Ireland.

BCC Research recently estimated that the vaccine business will advance at a blistering pace of 11 percent a year, hitting $34 billion in 2013. And Merck isn't alone in aggressively ramping up new facilities to satisfy the growing demand for vaccines. Sanofi-Aventis recently announced that it would invest more than $6 billion in its vaccine business and Microbix is spending almost $200 million on a new plant in China.

- read the article from In-PharmaTechnologist

Related Articles:
Merck's McGlynn has key role developing vaccines
Big Pharma takes an interest in cancer vaccines
Vaccine "renaissance" attracts huge new venture investments

More stories about Vaccine   Merck  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 59 + 11?
To combat spam, please solve the math question above.